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The link of biocompatibility to cytokine production. Recent reactants (APRs), and the magnitude and rapidity of
studies suggest that chronic inflammation plays a role in the their induction following an acute phase response, to-
pathogenesis of cardiovascular disease. Cytokines released from gether with their short half-life, suggest a particularly criti-jeopardized tissues stimulate the liver to synthesize acute phase
cal requirement in the establishment of host defense [2, 3].proteins, including C-reactive protein (CRP). Baseline levels of
More recently, the acute phase response has beenCRP in apparently healthy persons or in persons with unstable
angina constitute an independent risk factor for cardiovascular more narrowly defined as the change in concentrations
events. More recently, it has been suggested that CRP is useful of a number of plasma protein that results largely from
not only as a marker of the acute phase response, but is also
a rearrangement of plasma protein synthesis in hepato-involved in the pathogenesis of the disease. CRP may, in fact,
cytes. The proteins that manifest substantial change indirectly interact with the atherosclerotic vessels or ischemic
myocardium by activation of the complement system, thereby concentrations are referred to as the APRs (Fig. 1) [4, 5].
promoting inflammation and thrombosis. Several studies in Ceruloplasmin and the complement component C3
uremic patients have implicated CRP as a marker of malnutri- and C4 typically display only a modest acute phase re-
tion, resistance to erythropoietin, and chronic stimulation in
sponse, while aptoglobin and fibrinogen may increase two-hemodialysis. An increased cytokine production secondary to
fold to fivefold.blood interaction with bioincompatible dialysis components
has been reported by several studies; interleukin-1 (IL-1), tumor In contrast, the so-called negative APRs (albumin and
necrosis factor-a (TNF-a), and mainly IL-6 are the three proin- transferrin) are decreased in plasma concentration dur-
flammatory cytokines involved in the pathogenesis of hemodi- ing the acute phase response to allow an increase in thealysis-related disease. We have provided evidence for the oc-
capacity of the liver to synthesize the induced APRs.currence of high CRP and IL-6 levels in chronic dialytic patients
exposed to contaminate dialysate and suggest that backfiltration More strikingly, plasma levels of the so-called major
may induce a chronic, slowly developing inflammatory state that APRs can increase 1000-fold over normal levels; this
may be abrogated by avoiding backfiltration of contaminate group includes serum amyloid A (SAA) and C-reactive
dialysate. Therefore, CRP is implicated as a marker linking
protein (CRP) [6].bioincompatibility associated with backfiltration and increased
cytokine production with a clinical state of chronic inflammation.
STRUCTURE AND FUNCTION OF
C-REACTIVE PROTEINThe acute phase of the inflammatory response refers to
the wide-ranging physiological changes that are initiated Human CRP is a pentameric protein comprised of
immediately after an infection or physical trauma has five identical, noncovalently bound subunits, arranged
occurred [1]. in cyclic symmetry in a single plane [7]. The gene for the
The mammalian acute phase response is characterized CRP subunit in humans is encoded on chromosome 1 [8],
by fever and changes in vascular permeability, along and each subunit consists of a linear chain of 206 poly-
with profound changes in the biosynthetic profile of liver peptides with a single intrachain disulfide bond and a
proteins. calculated molecular weight of 23,017 (Fig. 2) [9, 10].
Under normal circumstances, the liver synthesizes a The protein is nonglycosylated and nonphosphory-
characteristic range of plasma proteins at a steady-state lated. Neither polymorphic forms nor isolated subunits
concentration. Many of these proteins have important have been observed in human in vivo.
functions and higher plasma levels of these acute phase The precise in vivo function of CRP is still uncertain;
nonetheless, several major and potentially important
types of biological activity of CRP have been well defined.Key words: inflammatory response, C-reactive protein, acute renal fail-
ure, uremia, dialysis. First, CRP is able to bind several biological substrates
that are widely distributed in nature. It was originallyÓ 2000 by the International Society of Nephrology
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Fig. 1. The acute phase response. Bacterial-derived fragments stimulate the monocytes/macrophage system to produce cytokines. Interleukin-6
(IL-6) is the major cytokine influencing the hepatic synthesis of acute phase protein. A modest increase for ceruloplasmin, C3, and C4 occurs;
haptoglobin and fibrinogen may increase twofold to fivefold. Albumin and transferrin plasma concentration are consistently reduced and are
referred as “negative” acute phase protein. The two major human positive, acute, phase proteins, C-reactive protein (CRP) and serum amyloid
A (SAA), may increase 1000-fold or more.
named for its ability to bind the pneumococcal C-poly- CRP BIOSYNTHESIS DURING THE ACUTE
PHASE RESPONSE: ROLE OF CYTOKINESsaccharide [11] and has been shown to have a number
of calcium-dependent binding specificities and biological Of the many soluble factors that initiate and maintain
activities related to nonspecific host defense. an inflammatory response, several hormones specifically
Second, it acts as an opsonin for bacteria, parasites, regulate the transcription of human ARP. These include
and immune complexes and can activate the classic path- interleukin-1 (IL-1), IL-6, tumor necrosis factor-a (TNF-a)
way of complement. leukemia inhibitory factor, transforming growth factor-b,
In addition, CRP can bind to chromatin, histones, and interferon-g, glucocorticoids, and the more recently iden-
small nuclear ribonucleoprotein particles. tified effector molecule IL-11 [14], oncostatin [15], ciliary
The ability to bind to and to effect the clearance of neutrophilic factor [16], and retinoic acid [17]. In addi-
nuclear material released from necrotic tissue during tion, insulin [18] and okadaic acid [19] have recently been
inflammation [12, 13] would provide an efficient means shown to act as inhibitors of the cytokine-driven induc-
of preventing the initiation of nuclear-antigen–specific tion of some ARP.
autoimmunity, and would explain, at least in part, the Some of these mediators are released initially at the
need for high levels of circulating pentraxins (such as site of inflammation by activated mononuclear phago-
cytes, lymphocytes, or other differentiated cell types andCRP and SAA) during inflammation.
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Fig. 2. Structure and function of CRP. Hu-
man CRP is a pentameric protein comprised
of five subunits arranged in cyclic symmetry.
The gene for each subunit is encoded on chro-
mosome 1, and the molecular weight of each
subunit is 23,017 D. Several well-defined bio-
logical functions of CRP are listed.
have potent local and systemic effects. However, IL-6 is Post-translation control of CRP secretion by rabbit
hepatocytes becomes more efficient during the acutefelt currently to be the major cytokine influencing acute
phase protein changes, while IL-1, TNF-a, transforming phase response [32], because of down-regulation of a
specific binding site by which CRP is normally retainedgrowth factor-b1, and interferon-g are also capable of
influencing synthesis of some plasma proteins in liver within the endoplasmic reticulum under nonacute phase
cells, and interactive effects of combinations of these conditions [33]. CRP can be further autoregulated by
cytokines have been shown [20–22]. CRP-mediated release from neutrophils of a protease
Elevated plasma levels of CRP are detectable as early that promote its own degradation [34].
as four hours following tissue injury, and peak levels are Thus, the dramatic transcriptional induction of CRP
attained within 24 to 72 hours [23]. The major source of by IL-6 is further enhanced by novel translation and
plasma CRP is the liver, and progressive recruitment of post-transitional mechanisms, which eventually lead to
hepatocytes [24] to CRP synthesis was found following a negative feedback loop in which CRP can down-regu-
experimental injury in the rabbit [25]. late its own levels during an inflammatory response.
Several in vitro studies of human CRP, using hepa- Following secretion, CRP appears to display a rapid
toma cells have shown that CRP mRNA transcription rate of plasma turnover in the rabbit, with a half-time
is induced dramatically by IL-6 [26, 27], with protein in the circulation of approximately four to five hours
synthesis being further regulated by translation and post- [35]. Studies in humans suggest a half-life of 18 hours
translation mechanisms. Although no significant changes [5], but during the inflammatory state, clearance may be
are elicited by IL-1b alone, when used in combination slightly more rapid [36]. The histologic observation that
with IL-6, there is a greatly enhanced response [28, 29]. CRP is deposited at local inflammatory sites is consistent
The promoter of the human CRP gene contains two with the possibility that there is enhanced clearance at
acute phase response elements (APREs). the site of inflammation [37].
These are APRE1, which contains a binding site for
the liver-specific transcription factor HNF1, and APRE2,
CRP AS A MARKER OFwhich contains an HNF1 binding site (b site) and an
CARDIOVASCULAR RISKIL-6 binding site (a site) [30].
Nuclear factor (NF)-IL-6 is a recently identified tran- Normally the acute phase response lasts only a few
days; however, in the case of chronic or recurring in-scription factor that is induced by IL-6 and activated by
protein kinase C-dependent phosphorylation at Ser 105. flammation, an aberrant continuation of some aspects
of the acute phase response may contribute to the under-It has the ability to interact with the promoter regions
of several IL-6–inducible genes at a consensus sequence lying tissue damage that accompanies the disease and
may also lead to further complications such as cardiovas-of TG/G/A AA [31].
In short, IL-6 activates NF IL-6, which interacts with cular diseases or reactive amyloidosis.
Laboratory-based evidence and epidemiological stud-the a site and enhances binding of NH1 to the b site, re-
sulting in the co-operative liver-specific induction of CRP. ies have investigated the association between coronary
heart disease and plasma protein involved in the acuteIn addition, post-transcriptional events are felt to par-
ticipate in acute phase protein induction. phase response [38].
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Two previous cross-sectional studies with detailed the extent of the acute phase reaction in response to
nonspecific stimuli such as confounding risk factors, ath-CRP values and cardiovascular risk factors are one in
300 British men [39] and the other in 400 older Ameri- erosclerosis, vascular injury, ischemia, and necrosis.
However, several arguments are against this explana-cans [40]. They made conflicting claims, particularly with
respect to the possible association between CRP and tion that increased plasma levels of CRP are merely an
epiphenomenon; in fact, there is increasing evidence thatsmoking status or serum lipids; however, the samples
were relatively small, and no attempts were made to avoid CRP is not only a marker of the acute phase response,
but is also involved in the pathogenesis of the disease.spurious association arising from a multiple comparison.
The prospective data of Ridker et al (Physician Health First, chronic infections that cause a rise in circulating
CRP also yield a higher risk for cardiovascular diseaseStudy) provide convincing evidence that the baseline
plasma concentrations of CRP in apparently healthy men [46–48]. Second, CRP is a cardiovascular risk factor even
after correction for other risk factors [41]. Finally, CRPare predictive of first myocardial infarction and ischemic
stroke, but not of venous thrombosis [41]. and activated complement factors can be found localized
in inflamed tissues [49], including atherosclerotic vesselsIn addition, the risk of arterial thrombosis associated
with the level of CRP was stable over long periods and [50] and infarcted myocardium [51].
Recently, Lagrand et al postulated the “flip-flop” hy-was not modified by other factors, including smoking
status, body mass index, blood pressure, plasma concen- pothesis. These authors suggested that membrane lyphos-
pholipids in ischemic myocardium may constitute ligandstration of total or high-density lipoprotein cholesterol,
triglyceride, lipoprotein, fibrinogen, or homocysteine. In for CRP [52].
The inner and outer leaflet of the cell membrane ofcontrast, the benefit of aspirin in reducing the risk of a
first myocardial infarction diminished significantly with normal cell differs in phospholipid composition: sphingo-
myelin and phosphatidylcoline being present in the outerdecreasing CRP concentrations. Finally, the study of
Ridker et al also suggests that CRP is not simply a short- leaflet and phosphatidylserine and phosphatidilethano-
lamine mainly in the inner leaflet. During apoptosis orterm marker of risk, as has previously been demonstrated
in patients with unstable angina, but is also a long-term ischemia, the asymmetry is lost, and the various phospho-
lipids of outer and inner leaflets exchange (flip-flop ofmarker of risk, even for events occurring six or more
years later. the membrane).
Thus, ligands for CRP may be generated in flip-flopThis observation made in men with favorable coronary
risk factor profiles expands on the results of previous cells with activation of the classic pathway of comple-
ment, and this activation subsequently enhances in-reports showing the long-term prognostic values of CRP
levels in people with multiple risk factors and in patients flammation and contributes to myocardial tissue damage
or dysfunction.with chronic angina [42].
The mechanisms that related the levels of CRP to This hypothesis predicts that high CRP levels will lead
to more intense CRP deposition and inflammatory reac-atherothrombosis are unclear. Previous infection with
Chlamydia pneumoniae, Helicobacter pylori [43], herpes, tions and hence tissue damages in the jeopardized myo-
cardium. It also explains why high-normal or slightlyor cytomegalovirus may be a source of the chronic in-
flammation detected by CRP. However, this seems un- increased baseline levels of plasma CRP constitute and
predict an increased risk for cardiovascular events withlikely because the risk association was found for values
obtained in 90% of normal people and was sustained the presence of phospholipids and membrane flip-flop
in the coronary vessels, which may result from short-over several years. In addition, Maseri found no evidence
of replicating cytomegalovirus in endarterectomy speci- term ischemic periods.
mens from unstable coronary plaques, but found an ab-
normal immunologic response in patients with unstable UREMIA AS A CHRONIC
angina and elevated CRP levels that was consistent with INFLAMMATORY STATE
previous report of leukocyte activation [44]. In fact, in-
Cardiovascular diseases still represent the largest sin-flammatory cells are commonly found in chronic athero-
gle cause of mortality in chronic renal failure patients,sclerosis, and evidence of immunologic activation in
and several risk factors are involved in the developmentplaques can be found in both acute and chronic ischemic
of atherogenesis in these patients.syndromes [45].
Strong and independent predictors of mortality or car-
diovascular diseases are low levels of serum albumin,
CRP AS A CARDIOVASCULAR RISK FACTOR: high plasma CRP, and lipoprotein (a), and all of these
MORE THAN AN EPIPHENOMENON? plasma proteins, described to function as negative or
positive APRs, are modulated by IL-6 [53].The link between CRP and cardiovascular risk is
thought to be indirect reflecting circulating CRP only The study by Kaizu et al demonstrated that the serum
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levels of IL-6 were significantly correlated with the major the authors postulated a role for this cytokine in athero-
genesis.parameters indicating malnutrition, such as body weight
loss and serum albumin level [54]. Even the more rapid Personal data (abstract; Panichi et al, Nephrol Dial
Transplant 13:A221, 1998) suggest that 25% of a popula-and sensitive index of malnutrition, such as prealbumin
and insulin-like growth factor-1, tended to be lower in tion of 102 chronic predialytic patients had CRP values
over 5 mg/L taken as the upper limit in normal humanpatients with high IL-6 levels.
The impact of protein intake and inflammation as sep- subjects (Fig. 3). These data could be even more dramatic
when we consider that in the study of Ridker et al, thearate independent factors in predicting serum albumin
levels in chronic hemodialytic patients was investigated risk of experiencing a cardiovascular accident was clearly
increased for CRP values over 3.1 mg/L [41]. CRP andby Kaysen et al, who found that the high concentration
of acute phase proteins have a greater impact on serum IL-6 were significantly related, and both were related
to renal function as plasma creatinine and creatininealbumin than low normalized polymerase chain reaction
(PCRn) [55]. This suggests the activity of APRs as an clearance.
important predictor of mortality independent of nutri-
tional factors.
CAN DIALYTIC MODALITIES INFLUENCE
Bergstro¨m et al stated that plasma CRP was the most
THIS CHRONIC INFLAMMATORY STATE?
powerful predictor of serum albumin levels, and that it
As stated earlier in this article, the role of inflamma-was a better predictor of death within the first year of
tion as a general pathway in the progression of vascularhemodialysis than was serum albumin (abstract, Berg-
and tissue damage in chronic uremic patients—associatedstro¨m et al, J Am Soc Nephrol 6:573, 1995) [56]. Further-
to anemia, cardiovascular disease, and malnutrition—ismore, proinflammatory cytokines that stimulate CRP syn-
well established.thesis also induce muscle catabolism with the liberation
Furthermore, hemodialysis may induce a chronic stim-of amino acids, inhibition of muscle protein synthesis [57],
ulation on the monocyte macrophage cellular compo-and anorexia [58].
nents via the exposure of the patient to a generally bioin-In conclusion, malnutrition is associated with mortality
compatible hemodialytic system.and morbidity of chronic uremic patients; the strong
In recent years, several studies have reported an in-correlation between chronic inflammation and protein
creased cytokine production secondary to blood interac-content among dialysis patients is mediated by the cyto-
tion with bioincompatible dialysis components. IL-1,kine-induced acute phase response.
TNF-a and mainly IL-6 are the three proinflammatoryIn addition, in chronic renal failure, plasma levels of
cytokines that are involved in the pathogenetical aspectsLp(a) are elevated, especially in patients with low plasma
of hemodialysis-related disease [62–66]. The proposedalbumin levels. A close relationship has been demon-
mechanisms include blood interaction with the hemodi-strated between high Lp(a) and CRP, sialic acid, and
alysis membrane and back-leakage of endotoxins fromIL-6 in hemodialysis patients [59]. These findings impli-
the contaminated dialysate through a high-flux dialysiscate that Lp(a) is elevated following an activation of
membrane.the acute phase response. In fact, seven IL-6–responsive
In fact, backfiltration and backdiffusion of contami-elements sequence can be identified in the flanking regu-
nated dialysate are the driving forces for the transmem-latory region of the Apo(a) gene of chromosome 6 [60].
brane passage of endotoxins or other cytokine-stimulat-Stenvinkel et al recently demonstrated that the rapidly
ing substances (CIS) during dialysis [67].developing atherosclerosis, studied by carotid B-mode
In a multicenter study, we measured the intracellularultrasonography, in advanced predialytic chronic renal
IL-1Ra and IL-1b concentrations in patients undergoingfailure appears to be caused by a synergism of different
low-volume exchange hemodiafiltration, which is knownmechanisms, such as malnutrition, oxidative stress, ge-
to be associated with backfiltration, in comparison tonetic factors, and chronic inflammation [61]. Apart from
those found in patients treated with a modified hemodia-classic risk factors, CRP levels are associated with an
filtration modality without backfiltration (paired filtra-increased intima-media area, whereas increased levels
tion dialysis) [68]. Hemodiafiltration with backfiltrationof oxidized low-density lipoprotein are associated with
was associated with a significant increase of IL-1Ra andthe presence of carotid plaques.
IL-1b.Patients with CRP levels over 10 mg/L had a significant
Nevertheless, conflicting results are present regardingincrease of mean cross-sectional calculated intima-media
the real impact of monocyte activation in several clinicalarea compared with patients with CRP , 10 mg/L. Also,
problems related to dialysis treatment. What is the clini-the mean lumen diameter was slightly but significantly
cal relevance of these observations in the clinical out-elevated in patients with elevated CRP.
come of chronic uremic patients?In this study, predialysis patients with carotid plaques
had significantly elevated plasma levels of TNF-a, and In a search for a clinical link with biocompatibility-
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Fig. 3. CRP distribution in chronic predia-
lytic and dialytic patients. CRP values over 5
mg/L were observed in 25% of a population
of 102 chronic clinically stable predialytic pa-
tients. In 303 chronic dialytic patients, 50% of
values resulted over 5 mg/L, taken as the up-
per limit in normal subjects. In particular, 43%
of these patients were between 5 and 20 mg/L
and 7% over 20 mg/L.
related cytokines production, we analyzed the APRs in
the same patients. The increased production of IL-1 and
IL-6 in patients exposed to backfiltration was associated
with a chronic inflammatory state, as reflected by in-
creased plasma proteins of acute phase as CRP [69].
To verify these findings in a larger population, we have
planned a multicenter cross-sectional and longitudinal
trial in over 300 clinically stable patients [70]. Patients
with clinical conditions known to be associated with
chronic inflammation and high CRP values such as amy-
loidosis, malnutrition, resistance to erythropoietin, and/or
clinically evident illness were excluded from the study.
Patients were treated with conventional hemodialysis,
hemodiafiltration with low exchange volume and high
Fig. 4. CRP values in a cross sectional and longitudinal survey. At
exchange volume, and double chamber hemodiafiltra- the starting time of the study, CRP values were significantly higher in
patients in low-volume (,10 L/session) hemodiafiltration in respecttion (paired filtration dialysis).
to patients treated by double-chamber hemodiafiltration (PFD), highC-reactive protein and IL-6 were measured at the be-
volume hemodiafiltration (.20 L/session), and standard hemodialysis.
ginning of the study and after six months of follow-up All patients were in the same dialytic modality for at least six months
before the start of the study. CRP values increased in patients in low-and resulted highly related.
volume hemodiafiltration after the six months of follow-up (*P , 0.05A large proportion (50%) of the global population analysis of variance and Student–Neumann–Keuls tests).
had CRP values over 5 mg/L, taken as the upper limit
in normal human subjects (Fig. 3). In particular, 43% of
the patients were between 5 and 20 mg/L, and 7% were
over 20 mg/L. monocyte/macrophages system by backfiltration of dial-
ysate contaminants [Limulus Amebocyte Lisate (LAL)-By analyzing these patients according to their different
dialytic modalities, a striking difference was present be- negative CIS]. There was, in fact, a significant increase
of CRP in low-volume but not in high-volume hemodia-tween low-volume (less than 10 L per session) hemodia-
filtration versus standard hemodialysis, high-volume hemo- filtration.
Ronco et al suggested that backfiltration may, in fact,diafiltration, and paired filtration dialysis (Fig. 4).
After six months of follow-up, CRP values in patients be dependent on ultrafiltration rate and dialyzer geome-
try: Increasing the ultrafiltration rate may drastically re-in hemodiafiltration with low exchange volume were
higher in regard to the values in the same patients deter- duce the risk of backfiltration that otherwise occurs with
low ultrafiltration rate as 2 L/hour [71]. Double-chambermined at the enrollment (Fig. 4).
We suggest that the increase of CRP in clinically stable hemodiafiltration, which eliminates backfiltration, was
associated with CRP values indistinguishable from thosedialytic patients may be due to the stimulation of the
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